Real-world data suggest anti-TNF biosimilars for juvenile idiopathic arthritis offer comparable efficacy and safety to their brand name counterparts. As high-cost originator biologics continue to ...

The addition of adalimumab biosimilars to formularies can help accelerate realized savings as the blockbuster drug Humira faces competition from multiple biosimilars, including 1 approved ...

Despite the influx of adalimumab biosimilars entering the market in 2023, Humira remains on top. As of January 2024, both high and low concentrations of Humira, the originator adalimumab product, are ...

BRIDGEWATER, N.J. and BENGALURU, India, July 3, 2023 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, today announced that HULIO® (adalimumab-fkjp) injection, a biosimilar to ...

In the last week, seven adalimumab biosimilars referencing HUMIRA entered the U.S. market: Boehringer Ingelheim’s CYLTEZO (adalimumab-adbm); Sandoz’s HYRIMOZ (adalimumab-adaz); Organon and Samsung ...

Please provide your email address to receive an email when new articles are posted on . Cigna Pharmacy announced that it will add adalimumab biosimilars as “preferred products” at the same price level ...

Biosimilars demonstrate comparable drug survival and safety with adalimumab among new users, but patients switching from Humira (the originator product) to biosimilars had a 35% higher discontinuation ...

Just about every Medicare Part D prescription drug plan on offer this year covers the original version of adalimumab (Humira), whereas only about half will pay for any of the several biosimilar ...

Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a blockbuster, appears to have led to a dramatic drop in net spending for these ...